Research Study

A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, STUDY TO ASSESS THE EFFICACY AND SAFETY OF LEBRIKIZUMAB IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS
Principal Investigator 
Nasreen Khalil

Overview

Body Locations and Systems 
Pulmonary Fibrosis
ClinicalTrials.gov# 
NCT01872689
Status 
Recruiting
Study Start/End 
Nov 27, 2013 to Aug 22, 2017
Locations 
Diamond Health Care Centre, Vancouver General Hospital
Name/Title 
Giselle Gerdak, Research Coordinator
Phone 
604-875-5091
Email Address 
giselle.gerdak@vch.ca
Purpose of Study 

This randomized, multicenter, double-blind, placebo-controlled, parallel-group s tudy will evaluate the efficacy and safety of lebrikizumab in patients with idio pathic pulmonary fibrosis. Patients will be randomized to receive either lebriki zumab or placebo subcutaneously (SC) every 4 weeks.

Eligibility 

Visit ClinicalTrials.gov for more information. 

Disclaimer 

Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific clinical research trials only. If you have specific questions which require clinical expertise, please call your primary care physician.